Evaluation of Adiponectin, Irisin, Vitamin D Levels and Their Relation in Iraqi Patients with Non alcoholic Fatty Liver Disease
Main Article Content
Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of chronic liver and defines by fat accumulation ≥5% in liver which can progresses to non-alcoholic steatohepatitis (NASH). NAFLD related to obesity as well as non obese individuals. Adiponectin is a cytokine secreted from adipose tissue involved NAFLD pathogenesis and liked with obesity. Irisin is a myokine, has a convenient effect against metabolic diseases such as obesity, disylipemia diabetes type 2 and reversed liver steatosis and may be related with NAFLD.
Vitamin D is one of the fat soluble vitamins and more precisely as a pro-hormone through its metabolite (1,25(OH)2 cholecalciferol) the major steroid hormone. After the skin exposure to the light, vitamin D undergoes to activation through two successive hydroxylation reactions in liver and kidney. Several metabolic diseases such as dyslipidaemia, obesity, hypertension, T2D and metabolic syndrome (MS) have been related to vitamin D deficiency.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
licenseTermsHow to Cite
Publication Dates
References
GRGUREVIC, Ivica; et al. Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020.
Mikolasevic, Ivana; et al. "Nonalcoholic fatty liver disease and liver transplantation-where do we stand?" World journal of gastroenterology 24.14 ,2018: 1491.
Yibby, María Luz Gunturiz Albarracína Ana, and Forero Torresb. "Adiponectin and Leptin Adipocytokines in Metabolic Syndrome: What Is Its Importance? Dubai Diabetes Endocrinol J 2020;26:93–102.
CHOI, Hyung Muk; DOSS, Hari Madhuri; KIM, Kyoung Soo. Multifaceted physiological roles of adiponectin in inflammation and diseases. International journal of molecular sciences, 2020, 21.4: 1219.
NGUYEN; Thi Mong Diep. Adiponectin: role in physiology and pathophysiology. International journal of preventive medicine, 2020, 11.
Enrique, Z Fisman; Alexander, Tenenbaum. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovascular Diabetology 2014, 13:103
Leustean, Letitia; et al. Role of Irisin in Endocrine and Metabolic Disorders—Possible New Therapeutic Agent?. Applied Sciences 11.12 ,2021: 5579.
Marrano, Nicola; et al. "Irisin and incretin hormones: Similarities, differences, and implications in type 2 diabetes and obesity." Biomolecules 11.2 ,2021: 286.
Ulualan, Gökçen, Z. E. Y. N. E. P. KÜSKÜ KİRAZ; BİRGÜL KIREL. Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics 64.2 2022.
Polyzos, S.A.; Anastasilakis, A.D.; Efstathiadou, Z.A.; Makras, P.; Perakakis, N.; Kountouras, J.; Mantzoros, C.S. Irisin in metabolic diseases. Endocrine 2018, 59, 260–274.
HU, Jie, et al. Circulating irisin levels in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology research and practice, 2020, 8818191.
DAHIYA, Kiran; PAL, Sanghapriya; DHANKHAR, Rakesh.Vitamin D in Physiological and Pathological Conditions. MedDocs eBooks, Resent Trends in Biochemistry. 2020.
Angle Gil; Julio Plaz-Diaz and Maria Dolores Mesa. Vitamin D: Classic and Novel Actions. Ann Nutr Metab. 2018,72: 87-95.
Mary S. Matsui. Vitamin D update. Current Dermatology Reports: 2020, 9: 323-330
Abramovitch S, Shirley, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut, 2011, 60.12: 1728-1737.
BORGES-CANHA, Marta, et al. The impact of vitamin D in non-alcoholic fatty liver disease: a cross-sectional study in patients with morbid obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, 14: 487.
CIMINI, Flavia A., et al. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World journal of gastroenterology, 2017, 23.19: 3407.
Wimalawansa SJ. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. J Steroid Biochem Mol Biol, 2018; 175: 177–189.
Nuttall, Frank Q. Body mass index: obesity, BMI, and health: a critical review. Nutrition today, 2015, 50.3: 117.
Daniel, Wayne W., and Chad L. Cross. Biostatistics: a foundation for analysis in the health sciences. 2018.
Johanna K. Disefano, Glenn S. Gerhard. NAFLD in Normal Weight Individuals. Diabetology and Metabolic Syndrome. (2022).14: 45
ZOU, Yang, et al. Association between the alanine aminotransferase/aspartate aminotransferase ratio and new-onset non-alcoholic fatty liver disease in a nonobese Chinese population: a population-based longitudinal study. Lipids in Health and Disease, 2020, 19.1: 1-10.
Lee, So-Ryoung, et al. Nonalcoholic fatty liver disease and the risk of atrial fibrillation stratified by body mass index: a nationwide population-based study. Scientific reports, 2021, 11.1: 1-9.
DIVELLA, Rosa, et al. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. International journal of biological sciences, 2019, 15.3: 610.
HOHENESTER, Simon, et al. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. American journal of physiology-gastrointestinal and liver physiology, 2018, 315.3: G329-G338.
YAMAUCHI, Toshimasa; KADOWAKI, Takashi. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell metabolism, 2013, 17.2: 185-196.
MOHAMED, Manal Sabry, et al. Correlation between adiponectin level and the degree of fibrosis in patients with non-alcoholic fatty liver disease. Egyptian Liver Journal, 2021, 11.1: 1-10.
PALACIOS‐GONZÁLEZ, Berenice, et al. Irisin levels before and after physical activity among school‐age children with different BMI: A direct relation with leptin. Obesity, 2015, 23.4: 729-732.
HU, Jie, et al. Circulating irisin levels in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology research and practice, 2020, 2020.
WANG, Ya-Di, et al. New insight of obesity-associated NAFLD: Dysregulated “crosstalk” between multi-organ and the liver?. Genes & Diseases, 2022.
SHANAKI, Mehrnoosh, et al. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes & metabolic syndrome: clinical research & reviews, 2017, 11: S467-S472.
ULUALAN, Gökçen; KÜSKÜ KİRAZ, ZEYNEP; KIREL, BİRGÜL. Relation of serum irisin levels to obesity and non-alcoholic fatty liver disease. Turkish Journal of Pediatrics, 2022, 64.2.
Jiang Q.; P.Yan; Y, Yang and S. Dai, Y. Luo. Correlation between Irisin Level and Insulin Resistance in Patients with Fatty Liver Disease. Modem Practical Medicine, 2017. 29, 11, 1440-1441, 2017.
HU, Jie, et al. Circulating irisin levels in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterology research and practice, 2020, 2020.
KARATAYLI, Ersin; STOKES, Caroline S.; LAMMERT, Frank. Vitamin D in preclinical models of fatty liver disease. Anticancer research, 2020, 40.1: 527-534.
BARCHETTA, Ilaria, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC medicine, 2011, 9.1: 1-7.
Dasarathy J; Periyalwar P;Allampati S; Bhinder V, Hawkins C, Brandt P, Khiyami A;McCullough AJ and Dasarathy S. Hypovitaminosis D is Associated with Increased Whole Body Fat Mass and Greater Severity of Non-Alcoholic Fatty liver Disease. Liver Int .2014. 34(6): 1
Nelson JE; Roth CL;Wilson LA;Yates KP; Aouizerat B; Morgan- Stevenson V; Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM and Kowdley KV. Vitamin D Deficiency is Associated with Increased Risk of Non-Alcoholic Steatohepatitis in Adults with Nonalcoholic Fatty Liver Disease: Possible Role for Mapk and Nf-kappab? Am J Gastroenterol. 2016.111(6): 852-863.
Nobili V; Giorgio V; Liccardo D; Bedogni G; Morino G; Alisi A and Cianfarani S. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol.2014,170(4): 547-553.
Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G and Arcaro G: Associations between serum 25-hydroxyvitamin d3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis .2007.17(7): 517-524.
Chung GE, Kim D, Kwak MS, Yang JI, Yim JY, Lim SH; Itani M: The serum vitamin d level is inversely correlated with nonalcoholic fatty liver disease. Clin Mol Hepatol.2016 22(1): 146-151.
Bril F, Maximos M, Portillo-Sanchez P, Biernacki D, Lomonaco R, Subbarayan S, Correa M, Lo M, Suman A and Cusi K. Relationship of Vitamin D with Insulin Resistance and Disease Severity in Non-Alcoholic Steatohepatitis. J Hepatol , 2015.62(2): 405-411.
Ilaria Barchetta, Francesco Angelico, Maria Del Ben, Marco Giorgio Baroni, Paolo Pozzilli, Sergio Morini;Maria Gisella Cavallo. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine. 2011, 9:85
Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38 (3):246–254.
Liangpunsakul S and Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci. 2011;56 (7):2124–2129.
Eliades M, Spyrou E. Vitamin D: a new player in non-alcoholic fatty liver disease? World.J.Gastroenterol.2015;21(6):1718–1727.
Yunkoo Kang., Sowon Park, Seung Kim; Hog Koh. Normal Serum Alanine Aminotrasferase and Non-Alcoholic Fatty Liver Disease Among Korean Adolescents: A Cross-Sectional study Using Data from KNHANES 2010-2015. BMC Pediatrics. 2018. 18: 215 .
Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez- Cantero A, Arrebola JP and Gonzalez- Calvin JL. Diagnostic Accuracy of Serum Alanin Aminotransferase as Biomarker for Nonalcoholic Fatty Liver Desaes and Insulin Resistance in Healthy Subjects Using 3T MR Spectroscopy. Medicine (Baltimore). 2017 ; 96: e6770
Isaken VT. Larsen MA, Goll R, Florholmen JR and Paulssen EJ. Hepatic Steatosis, Detected by Hepatorenal Index in Ultrasonography, As A Predictor of Insulin Resistance in Obese Subjects. BMC Obes. 2016,3:39.
Bishnu Jwarchan, Subita Lalchan, Anil Dhakal and Ramesh R Acharya. Comparison of Liver Enzymes and Sonological Grading in Nonalcoholic Fatty Liver. Asian J Medical Sciences. 2020 ,11: 2
Eri Ozaki, Hirotaka Ochiai, Takako shirasawa, et al. Eating Quickly is Associated with A Low Aspartate Aminotrasferase to Alanine aminotrasferase Ratio in Middle-Age Adults: A Large-Scale Cross-Sectional Survey in Japan. Arch. Pub Health. 2020 ,78: 101.
Yu Z hang, He He, Yu-Ping Zeng, Li-Dan Yang, Dan Jia, Zhen-Mei An and Wei-Guo Jia. Lipoprotein A Combined with Alanine Aminotransferase and Aspartate Aminotransferase, Contributes to Predicting The Occurrence of NASH: A Cross-Sectional Study. Lipids in Health and Disease. 2020 ,19: 134.
Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella. Non-alcoholic fatty liver disease. Lancet .2021; 397: 2212–24
Chalasani N., Younossi Z., Lavine JE., Charlton M., Cui K., Rinella M., Harrison SA., et al The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from The American Association for The Study of Liver Diseases. Hepatology. 2018, 67: 328-357.
Xuefeng Ma, Shousheng Liu, Jie Zhang , Mengzhen Dong, Yifen Wang, Mengke Wang and Yongning Xin. Proportion of NAFLD Patients with Normal ALT Value in Overall NAFLD